Twin epidemics: The surging rise of methamphetamine use in chronic opioid users
•Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other. Background/aims: Recent supply-side efforts enacted to c...
Saved in:
Published in | Drug and alcohol dependence Vol. 193; pp. 14 - 20 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.12.2018
Elsevier Science Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other.
Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.
Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.
Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).
Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine. |
---|---|
AbstractList | Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.
Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.
Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).
Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine. •Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other. Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine. Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.BACKGROUND/AIMSRecent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.METHODSPatients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).RESULTSPast month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.CONCLUSIONSOur studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine. Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine. |
Author | Kasper, Zachary A. Cicero, Theodore J. Ellis, Matthew S. |
Author_xml | – sequence: 1 givenname: Matthew S. surname: Ellis fullname: Ellis, Matthew S. email: ellism@wustl.edu – sequence: 2 givenname: Zachary A. surname: Kasper fullname: Kasper, Zachary A. – sequence: 3 givenname: Theodore J. surname: Cicero fullname: Cicero, Theodore J. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30326396$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1v1DAQhi1URLeFv4AiceGSxR9Zx-aAgIoWpEq9LGfLcSa7syR2sBNQ_z2OthXSntYaydL4mXfG816RCx88EFIwumaUyQ-HdRvnne1dC-OaU6bWNAfXL8iKqVqXlFbygqyoqGWpaiYvyVVKB5qP1PQVuRRUcCm0XJGH7V_0BYzYwoAufSy2eyjSHHfod0XEBEXoigGmvR3GPUx2QA_FnNO5yu1j8OiKMGLAdsnG9Jq87Gyf4M3TfU1-3n7b3nwv7x_uftx8uS9dtdFT2WwqyhuoVMNsS52kTOeBmMqPzLqm0g2wTljQlAu1oYqpRje1kh3UFa9Ai2vy_qg7xvB7hjSZAZODvrcewpwMZ5xV-eucZfTdCXoIc_R5ukxt6qoWTCzU2ydqbgZozRhxsPHRPK8qA5-OgIshpQidcTjZCYOfosXeMGoWb8zB_PfGLN4YmoMvI6sTgeceZ5R-PZZCXukfhGiSQ_AOWozgJtMGPEfk84mI6zH7Z_tf8HiexD_1G8PW |
CitedBy_id | crossref_primary_10_1111_dar_13918 crossref_primary_10_1136_openhrt_2021_001930 crossref_primary_10_1001_jamanetworkopen_2023_41921 crossref_primary_10_1080_10826084_2021_2003404 crossref_primary_10_1016_j_drugalcdep_2022_109341 crossref_primary_10_1016_j_drugalcdep_2022_109469 crossref_primary_10_1016_j_dadr_2023_100163 crossref_primary_10_31389_jied_122 crossref_primary_10_1111_add_16760 crossref_primary_10_1016_j_mcna_2023_06_017 crossref_primary_10_1016_j_drugpo_2022_103584 crossref_primary_10_1016_j_drugpo_2023_104150 crossref_primary_10_1186_s13722_021_00267_1 crossref_primary_10_3389_fpsyt_2021_784229 crossref_primary_10_3390_v12111297 crossref_primary_10_1371_journal_pone_0245920 crossref_primary_10_1080_15563650_2020_1853143 crossref_primary_10_2105_AJPH_2020_305748 crossref_primary_10_1007_s11121_021_01215_w crossref_primary_10_1016_j_jsat_2020_01_010 crossref_primary_10_1177_0022042620959071 crossref_primary_10_3389_fnins_2020_00569 crossref_primary_10_1371_journal_pmed_1002969 crossref_primary_10_1080_14737167_2024_2350561 crossref_primary_10_1186_s13011_021_00350_5 crossref_primary_10_1186_s13722_022_00322_5 crossref_primary_10_1016_j_jsat_2021_108461 crossref_primary_10_1016_j_neubiorev_2022_104714 crossref_primary_10_1007_s10461_022_03605_9 crossref_primary_10_1146_annurev_pharmtox_030220_124205 crossref_primary_10_1093_aje_kwab290 crossref_primary_10_1016_j_drugalcdep_2024_111098 crossref_primary_10_1093_sleep_zsab001 crossref_primary_10_1001_jamanetworkopen_2022_11641 crossref_primary_10_1186_s12954_023_00816_8 crossref_primary_10_1186_s12954_024_00928_9 crossref_primary_10_1016_j_jcrimjus_2024_102167 crossref_primary_10_1016_j_drugalcdep_2021_108750 crossref_primary_10_1016_j_cppeds_2022_101265 crossref_primary_10_1016_j_drugalcdep_2020_108357 crossref_primary_10_1111_dar_13261 crossref_primary_10_1111_1556_4029_15373 crossref_primary_10_1016_j_ajem_2023_01_042 crossref_primary_10_1111_jrh_12743 crossref_primary_10_1097_ADM_0000000000000824 crossref_primary_10_1186_s13722_021_00266_2 crossref_primary_10_1016_j_josat_2023_208956 crossref_primary_10_1186_s12954_022_00721_6 crossref_primary_10_1016_j_apnu_2024_07_007 crossref_primary_10_1016_j_amepre_2024_10_012 crossref_primary_10_1016_j_pmedr_2023_102494 crossref_primary_10_1186_s12889_022_14506_w crossref_primary_10_3389_fpsyt_2021_805002 crossref_primary_10_1186_s12889_022_12678_z crossref_primary_10_1192_bjp_2023_111 crossref_primary_10_1016_j_drugalcdep_2021_108767 crossref_primary_10_1016_j_drugalcdep_2021_108527 crossref_primary_10_1016_j_josat_2023_209012 crossref_primary_10_1177_07067437221125302 crossref_primary_10_1080_00952990_2021_1981919 crossref_primary_10_1001_jamanetworkopen_2022_11634 crossref_primary_10_1016_j_ypmed_2021_106729 crossref_primary_10_2147_NDT_S331442 crossref_primary_10_1097_JAN_0000000000000298 crossref_primary_10_2196_45717 crossref_primary_10_1016_j_jsat_2022_108830 crossref_primary_10_1080_10826084_2021_1975747 crossref_primary_10_1016_j_drugalcdep_2021_109145 crossref_primary_10_1016_j_drugalcdep_2019_01_045 crossref_primary_10_1016_j_drugalcdep_2020_108333 crossref_primary_10_1111_ajad_13619 crossref_primary_10_1007_s13181_022_00924_0 crossref_primary_10_1159_000519541 crossref_primary_10_1124_jpet_119_258699 crossref_primary_10_1080_14659891_2022_2157770 crossref_primary_10_2105_AJPH_2021_306373 crossref_primary_10_1097_ADM_0000000000000726 crossref_primary_10_1016_j_abrep_2021_100353 crossref_primary_10_3389_fgene_2022_837123 crossref_primary_10_1016_j_jsat_2021_108666 crossref_primary_10_1016_j_drugalcdep_2019_107592 crossref_primary_10_1016_j_nicl_2019_102068 crossref_primary_10_3389_fphar_2022_859563 crossref_primary_10_1080_02791072_2025_2478090 crossref_primary_10_1016_j_drugalcdep_2022_109535 crossref_primary_10_1016_j_drugalcdep_2020_108323 crossref_primary_10_1111_dar_13690 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_108178 crossref_primary_10_1097_ADM_0000000000000611 crossref_primary_10_1186_s12954_024_00976_1 crossref_primary_10_1016_j_drugpo_2020_103098 crossref_primary_10_1080_15563650_2024_2391011 crossref_primary_10_3390_ijerph192416759 crossref_primary_10_1111_add_16147 crossref_primary_10_1186_s13063_021_05919_w crossref_primary_10_1186_s13722_023_00402_0 crossref_primary_10_3390_ijerph182111072 crossref_primary_10_1016_j_addbeh_2020_106379 crossref_primary_10_1016_j_josat_2024_209614 crossref_primary_10_1080_10826084_2020_1765805 crossref_primary_10_1097_ADM_0000000000001035 crossref_primary_10_1891_JDNP_2023_0019 crossref_primary_10_1016_j_drugalcdep_2023_110956 crossref_primary_10_1177_29768357241272374 crossref_primary_10_1111_adb_12831 crossref_primary_10_1080_10826084_2021_1963987 crossref_primary_10_1016_j_drugalcdep_2021_108719 crossref_primary_10_1186_s13011_021_00414_6 crossref_primary_10_2196_48405 crossref_primary_10_1186_s12889_021_11783_9 crossref_primary_10_1097_MLR_0000000000001460 crossref_primary_10_3389_fpsyt_2021_804997 crossref_primary_10_1093_infdis_jiaa129 crossref_primary_10_1093_epirev_mxaa011 crossref_primary_10_3390_ijerph19042230 crossref_primary_10_1016_j_ypmed_2020_106194 crossref_primary_10_1097_CXA_0000000000000068 crossref_primary_10_1016_j_drugalcdep_2021_109256 crossref_primary_10_1093_infdis_jiaa005 crossref_primary_10_1016_j_drugalcdep_2021_108844 crossref_primary_10_1016_j_abrep_2020_100289 crossref_primary_10_1080_10550887_2021_2005382 crossref_primary_10_1186_s13722_023_00364_3 crossref_primary_10_1001_jamapsychiatry_2021_2588 crossref_primary_10_1177_10249079231179103 crossref_primary_10_1097_ADM_0000000000000876 crossref_primary_10_1097_ADT_0000000000000253 crossref_primary_10_3389_fsoc_2020_593925 crossref_primary_10_1007_s00127_023_02500_5 crossref_primary_10_1007_s11469_023_01134_7 crossref_primary_10_1080_23279095_2022_2164197 crossref_primary_10_1016_j_drugpo_2022_103592 crossref_primary_10_1007_s00213_019_05399_6 crossref_primary_10_1016_j_drugalcdep_2025_112630 crossref_primary_10_1111_nyas_14688 crossref_primary_10_1111_add_15954 crossref_primary_10_1016_j_drugalcdep_2022_109740 crossref_primary_10_1001_jamanetworkopen_2024_41063 crossref_primary_10_1002_jaba_2911 crossref_primary_10_1016_j_josat_2023_209079 crossref_primary_10_1177_07067437231158933 crossref_primary_10_1080_14659891_2020_1738573 crossref_primary_10_1016_j_drugpo_2021_103463 crossref_primary_10_1080_10826084_2023_2287220 crossref_primary_10_1016_j_josat_2024_209365 crossref_primary_10_1016_j_drugalcdep_2020_108416 crossref_primary_10_1176_appi_prcp_20240051 crossref_primary_10_1111_add_15714 crossref_primary_10_1016_j_drugalcdep_2024_111133 crossref_primary_10_1186_s12916_024_03646_y crossref_primary_10_1016_j_saa_2024_125234 crossref_primary_10_1177_00220426241231720 crossref_primary_10_1186_s13011_022_00470_6 crossref_primary_10_1016_j_drugalcdep_2020_108084 crossref_primary_10_1111_add_14755 crossref_primary_10_3389_fpsyt_2022_918197 crossref_primary_10_1007_s11469_023_01098_8 crossref_primary_10_1080_02791072_2021_2006374 crossref_primary_10_1007_s40429_025_00625_y crossref_primary_10_1016_j_drugalcdep_2021_108702 crossref_primary_10_1136_bmjopen_2021_059898 crossref_primary_10_1080_07359683_2024_2380118 crossref_primary_10_1080_08897077_2021_1946892 crossref_primary_10_1080_13218719_2023_2206870 crossref_primary_10_1016_j_addicn_2025_100204 crossref_primary_10_1186_s12954_024_00986_z crossref_primary_10_1186_s13011_022_00504_z crossref_primary_10_15585_mmwr_mm6834a2 crossref_primary_10_1108_IJOPH_12_2023_0084 crossref_primary_10_1080_03007995_2024_2333429 crossref_primary_10_7759_cureus_36468 crossref_primary_10_1016_j_drugalcdep_2020_108193 crossref_primary_10_1080_15332640_2022_2109790 crossref_primary_10_1016_j_mcna_2021_08_010 crossref_primary_10_1136_bmjopen_2021_060447 crossref_primary_10_1016_j_drugalcdep_2023_110911 crossref_primary_10_3389_fpsyg_2021_689483 crossref_primary_10_1097_ADM_0000000000000667 crossref_primary_10_1097_ADM_0000000000000669 crossref_primary_10_1371_journal_pone_0252090 crossref_primary_10_1016_j_drugalcdep_2019_107574 crossref_primary_10_1016_j_josat_2022_208934 crossref_primary_10_1186_s12905_020_01088_1 crossref_primary_10_1097_ADM_0000000000001095 crossref_primary_10_1186_s12954_022_00630_8 crossref_primary_10_1093_ofid_ofac708 crossref_primary_10_1080_17512433_2023_2279192 crossref_primary_10_1080_14659891_2024_2423616 crossref_primary_10_1007_s10461_021_03381_y crossref_primary_10_3389_fpsyt_2020_00750 crossref_primary_10_1080_16066359_2023_2167982 crossref_primary_10_1007_s11121_023_01602_5 crossref_primary_10_3389_fpsyt_2021_786056 crossref_primary_10_1186_s12954_021_00500_9 crossref_primary_10_1016_j_amepre_2023_10_002 crossref_primary_10_1097_AOG_0000000000003907 crossref_primary_10_1093_infdis_jiz445 crossref_primary_10_1080_10826084_2021_1949612 crossref_primary_10_1016_j_addbeh_2020_106752 crossref_primary_10_1016_j_josat_2023_208982 crossref_primary_10_1016_j_nurpra_2021_02_011 crossref_primary_10_1111_dar_13955 crossref_primary_10_1016_j_socscimed_2025_117843 crossref_primary_10_1080_14659891_2020_1808724 crossref_primary_10_1016_j_josat_2025_209685 crossref_primary_10_1186_s12879_020_05464_y crossref_primary_10_1016_j_bcp_2024_116189 crossref_primary_10_1001_jamanetworkopen_2022_43653 crossref_primary_10_3390_ijms231710092 crossref_primary_10_1007_s11469_024_01378_x crossref_primary_10_1111_add_16334 crossref_primary_10_1177_00220426241277763 crossref_primary_10_3389_fpsyt_2022_824940 crossref_primary_10_1093_cid_ciaa064 crossref_primary_10_1177_11782218231180043 crossref_primary_10_3390_ijms231911224 crossref_primary_10_3389_fpsyt_2022_835816 crossref_primary_10_1056_NEJMoa2020214 crossref_primary_10_1186_s12954_023_00782_1 crossref_primary_10_3390_ijerph20010543 crossref_primary_10_1177_00027162231154348 crossref_primary_10_1097_ADM_0000000000000695 crossref_primary_10_62401_2531_4122_2024_24 crossref_primary_10_1007_s10461_021_03460_0 crossref_primary_10_1080_1533256X_2023_2294287 crossref_primary_10_1080_15563650_2022_2038793 crossref_primary_10_2196_21212 crossref_primary_10_1186_s12889_020_09856_2 crossref_primary_10_1016_j_jpsychires_2023_05_018 crossref_primary_10_1186_s13063_022_06278_w crossref_primary_10_1016_j_jsat_2022_108894 crossref_primary_10_1177_26334895211005809 crossref_primary_10_1371_journal_pone_0242165 crossref_primary_10_1186_s13722_023_00382_1 crossref_primary_10_1016_j_drugpo_2022_103879 crossref_primary_10_1097_CXA_0000000000000211 crossref_primary_10_3389_fpubh_2024_1279477 crossref_primary_10_1016_j_annemergmed_2020_06_046 crossref_primary_10_1016_j_bbr_2022_113876 crossref_primary_10_3390_vaccines10091508 crossref_primary_10_1177_08897077231199572 crossref_primary_10_1001_jamapsychiatry_2020_0246 crossref_primary_10_1186_s12954_022_00588_7 crossref_primary_10_1016_j_drugalcdep_2022_109274 crossref_primary_10_1177_02537176241236899 crossref_primary_10_1016_j_josat_2024_209589 crossref_primary_10_1016_j_drugalcdep_2020_108261 crossref_primary_10_1111_dar_13863 crossref_primary_10_1177_0022042619895247 crossref_primary_10_1016_j_drugalcdep_2020_108384 crossref_primary_10_1186_s13033_021_00512_9 crossref_primary_10_2105_AJPH_2019_305527 crossref_primary_10_1177_21501319231161208 crossref_primary_10_2105_AJPH_2019_305412 crossref_primary_10_1016_j_drugpo_2023_104103 crossref_primary_10_1111_add_14812 crossref_primary_10_1016_j_drugpo_2023_104222 crossref_primary_10_1186_s12954_024_01129_0 |
Cites_doi | 10.1056/NEJMsa1406143 10.1111/j.1465-3362.2011.00291.x 10.15585/mmwr.mm6626a4 10.1016/j.neuroscience.2016.01.043 10.1056/NEJMra1508490 10.1016/j.emc.2015.11.002 10.1056/NEJMp1512932 10.15585/mmwr.mm6712a1 10.1016/j.brainresbull.2017.06.008 10.1177/003335491412900207 10.1016/j.drugalcdep.2016.03.014 10.1016/j.ajp.2018.02.004 10.1021/jacs.7b03334 10.15252/embr.201745322 10.15585/mmwr.mm6643e1 10.1016/j.jsat.2014.08.004 10.1213/ANE.0000000000002403 10.1080/15332640.2015.1070392 10.1111/j.1526-4637.2006.00259.x 10.1001/jamapsychiatry.2014.366 10.1001/jamapsychiatry.2014.3043 10.15288/jsad.2016.77.774 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Dec 1, 2018 |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Dec 1, 2018 |
DBID | AAYXX CITATION NPM 7QJ 7TK 7U7 C1K K9. NAPCQ 7X8 |
DOI | 10.1016/j.drugalcdep.2018.08.029 |
DatabaseName | CrossRef PubMed Applied Social Sciences Index & Abstracts (ASSIA) Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Toxicology Abstracts Applied Social Sciences Index and Abstracts (ASSIA) Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
EISSN | 1879-0046 |
EndPage | 20 |
ExternalDocumentID | 30326396 10_1016_j_drugalcdep_2018_08_029 S0376871618306872 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US |
GeographicLocations_xml | – name: United States--US |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM 9JO AABNK AAEDT AAEDW AAFJI AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXLA AAXUO ABBQC ABCQJ ABFNM ABIVO ABJNI ABLJU ABMAC ABMMH ABMZM ABZDS ACDAQ ACGFS ACHQT ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP AVARZ AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM M29 M39 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OH0 OU- OZT P-8 P-9 P2P PC. PRBVW Q38 ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSB SSH SSN SSO SSP SSZ T5K TN5 WH7 Z5R ~G- AACTN AADPK AAIAV AATCM ABLVK ABYKQ AFKWA AJOXV AKYCK AMFUW EFLBG LCYCR RIG .GJ 29G 53G AAQXK AAYWO AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AGQPQ AGRNS AIGII ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEG HMK HMO HVGLF HZ~ H~9 R2- SEW UAP WUQ XPP ZGI ZXP ZY4 NPM 7QJ 7TK 7U7 C1K K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c459t-b5402be48b1ad0c6019263184591acb49be1f3ae9023850818b9b786fe7424e93 |
IEDL.DBID | .~1 |
ISSN | 0376-8716 1879-0046 |
IngestDate | Wed Jul 30 11:16:30 EDT 2025 Wed Aug 13 06:14:35 EDT 2025 Thu Apr 03 07:04:46 EDT 2025 Tue Jul 01 01:53:29 EDT 2025 Thu Apr 24 23:04:35 EDT 2025 Fri Feb 23 02:24:25 EST 2024 Tue Aug 26 20:29:13 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Polysubstance use Methamphetamine Opioids |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459t-b5402be48b1ad0c6019263184591acb49be1f3ae9023850818b9b786fe7424e93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 30326396 |
PQID | 2157473131 |
PQPubID | 2033333 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2121487121 proquest_journals_2157473131 pubmed_primary_30326396 crossref_citationtrail_10_1016_j_drugalcdep_2018_08_029 crossref_primary_10_1016_j_drugalcdep_2018_08_029 elsevier_sciencedirect_doi_10_1016_j_drugalcdep_2018_08_029 elsevier_clinicalkey_doi_10_1016_j_drugalcdep_2018_08_029 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-12-01 2018-12-00 20181201 |
PublicationDateYYYYMMDD | 2018-12-01 |
PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland – name: Lausanne |
PublicationTitle | Drug and alcohol dependence |
PublicationTitleAlternate | Drug Alcohol Depend |
PublicationYear | 2018 |
Publisher | Elsevier B.V Elsevier Science Ltd |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
References | International Narcotics Control Board (bib0075) 2009 U.S. Customs and Border Protection (bib0150) 2018 Cicero, Ellis (bib0030) 2015; 72 Brady, Wunsch, DiMaggio, Lang, Giglio, Li (bib0010) 2014; 129 Meacham, Strathdee, Rangel, Armenta, Gaines, Garfein (bib0105) 2016; 77 Cicero, Ellis, Surratt, Kurtz (bib0040) 2014; 71 Mori, Iwase, Saeki, Iwata, Murata, Masukawa, Suzuki (bib0115) 2016; 322 Robles (bib0135) 2018 Soelberg, Brown, Du Vivier, Meyer, Ramachandran (bib0145) 2017; 125 Dart, Surratt, Cicero, Parrino, Severtson, Bucher-Bartelson, Green (bib0060) 2015; 372 Alford (bib0005) 2016; 374 Center for Substance Abuse Treatment (bib0025) 2004 McHugh, Nielsen, Weiss (bib0100) 2015; 48 Compton, Jones, Baldwin (bib0050) 2016; 374 U.S. Department of Justice, Drug Enforcement Administration (bib0155) 2017 Center for Behavioral Health Statistics and Quality (bib0020) 2015 Kuppili, Manohar, Menon (bib0080) 2018; 31 Dart, Surratt, Cicero, Parrino, Severtson, Bucher-Bartelson, Green (bib0055) 2015; 372 Seth, Scholl, Rudd, Bacon (bib0140) 2018; 67 Guy, Zhang, Bohm, Losby, Lewis, Young, Murphy, Dowell (bib0070) 2017; 66 DuPont (bib0065) 2018; 138 National Institute on Drug Abuse (bib0120) 2018 Maxwell (bib0095) 2011; 30 Montemayor (bib0110) 2018 Cicero, Ellis, Kasper (bib0045) 2017; 173 Lipari, Williams, Van Horn (bib0085) 2017 O’Donnell, Halpin, Mattson, Goldberger, Gladden (bib0125) 2017; 66 Olson, Janda (bib0130) 2018; 19 Bremer, Schlosburg, Banks, Steele, Zhou, Poklis, Janda (bib0015) 2017; 139 Cicero, Dart, Indiardi, Woody, Schnoll, Munoz (bib0035) 2007; 8 Wilkerson, Kim, Windsor, Mareiniss (bib0160) 2016; 34 Loza, Ramos, Ferreira-Pinto, Hernandez, Villalobos (bib0090) 2016; 15 McHugh (10.1016/j.drugalcdep.2018.08.029_bib0100) 2015; 48 Cicero (10.1016/j.drugalcdep.2018.08.029_bib0035) 2007; 8 Maxwell (10.1016/j.drugalcdep.2018.08.029_bib0095) 2011; 30 O’Donnell (10.1016/j.drugalcdep.2018.08.029_bib0125) 2017; 66 Mori (10.1016/j.drugalcdep.2018.08.029_bib0115) 2016; 322 International Narcotics Control Board (10.1016/j.drugalcdep.2018.08.029_bib0075) 2009 Seth (10.1016/j.drugalcdep.2018.08.029_bib0140) 2018; 67 Cicero (10.1016/j.drugalcdep.2018.08.029_bib0040) 2014; 71 Dart (10.1016/j.drugalcdep.2018.08.029_bib0055) 2015; 372 Soelberg (10.1016/j.drugalcdep.2018.08.029_bib0145) 2017; 125 Bremer (10.1016/j.drugalcdep.2018.08.029_bib0015) 2017; 139 Lipari (10.1016/j.drugalcdep.2018.08.029_bib0085) 2017 U.S. Customs and Border Protection (10.1016/j.drugalcdep.2018.08.029_bib0150) 2018 Compton (10.1016/j.drugalcdep.2018.08.029_bib0050) 2016; 374 Kuppili (10.1016/j.drugalcdep.2018.08.029_bib0080) 2018; 31 Loza (10.1016/j.drugalcdep.2018.08.029_bib0090) 2016; 15 Alford (10.1016/j.drugalcdep.2018.08.029_bib0005) 2016; 374 Brady (10.1016/j.drugalcdep.2018.08.029_bib0010) 2014; 129 Meacham (10.1016/j.drugalcdep.2018.08.029_bib0105) 2016; 77 Guy (10.1016/j.drugalcdep.2018.08.029_bib0070) 2017; 66 Olson (10.1016/j.drugalcdep.2018.08.029_bib0130) 2018; 19 Robles (10.1016/j.drugalcdep.2018.08.029_bib0135) 2018 Montemayor (10.1016/j.drugalcdep.2018.08.029_bib0110) 2018 U.S. Department of Justice, Drug Enforcement Administration (10.1016/j.drugalcdep.2018.08.029_bib0155) 2017 National Institute on Drug Abuse (10.1016/j.drugalcdep.2018.08.029_bib0120) 2018 Cicero (10.1016/j.drugalcdep.2018.08.029_bib0030) 2015; 72 Center for Behavioral Health Statistics and Quality (10.1016/j.drugalcdep.2018.08.029_bib0020) 2015 Cicero (10.1016/j.drugalcdep.2018.08.029_bib0045) 2017; 173 DuPont (10.1016/j.drugalcdep.2018.08.029_bib0065) 2018; 138 Wilkerson (10.1016/j.drugalcdep.2018.08.029_bib0160) 2016; 34 Center for Substance Abuse Treatment (10.1016/j.drugalcdep.2018.08.029_bib0025) 2004 Dart (10.1016/j.drugalcdep.2018.08.029_bib0060) 2015; 372 |
References_xml | – volume: 374 start-page: 154 year: 2016 end-page: 163 ident: bib0050 article-title: Relationship between nonmedical prescription-opioid use and heroin use publication-title: N. Engl. J. Med. – volume: 48 start-page: 1 year: 2015 end-page: 7 ident: bib0100 article-title: Prescription drug abuse: from epidemiology to public policy publication-title: J. Subst. Abuse Treat. – volume: 19 start-page: 5 year: 2018 end-page: 9 ident: bib0130 article-title: Vaccines to combat the opioid crisis. Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse publication-title: EMBO Rep. – year: 2018 ident: bib0110 article-title: In the Shadow of the Opioid Crisis, Meth Has Roared Back into Minnesota – volume: 72 start-page: 424 year: 2015 end-page: 430 ident: bib0030 article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin publication-title: JAMA Psychiatry – year: 2018 ident: bib0120 article-title: National Survey of Drug Use and Health: Trends in Prevalence of Various Drugs from Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015–2016 – volume: 322 start-page: 164 year: 2016 end-page: 170 ident: bib0115 article-title: Differential activation of dopaminergic systems in rat brain basal ganglia by morphine and methamphetamine publication-title: Neuroscience – volume: 173 start-page: S4 year: 2017 end-page: S10 ident: bib0045 article-title: Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter? publication-title: Drug Alcohol Depend. – volume: 138 start-page: 112 year: 2018 end-page: 114 ident: bib0065 article-title: The opioid epidemic is an historic opportunity to improve both prevention and treatment publication-title: Brain Res. Bull. – year: 2017 ident: bib0155 article-title: 2017 National Drug Threat Assessment. DEA-DCT-DIR-040-17 – volume: 372 start-page: 241 year: 2015 end-page: 248 ident: bib0055 article-title: Trends in opioid analgesic abuse and mortality in the United States publication-title: N. Engl. J. Med. – year: 2018 ident: bib0135 article-title: Meth, the Forgotten Killer, is Back. And It’s Everywhere – year: 2015 ident: bib0020 article-title: Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50 – year: 2009 ident: bib0075 article-title: Report of the International Narcotics Control Board for 2008 – volume: 34 start-page: e1 year: 2016 end-page: e23 ident: bib0160 article-title: The opioid epidemic in the United States publication-title: Emerg. Med. Clin. North Am. – volume: 30 start-page: 264 year: 2011 end-page: 270 ident: bib0095 article-title: The prescription drug epidemic in the United States: a perfect storm publication-title: Drug Alcohol Rev. – year: 2017 ident: bib0085 article-title: Why Do Adults Misuse Prescription Drugs? The CBHSQ Report – volume: 66 start-page: 1197 year: 2017 end-page: 1202 ident: bib0125 article-title: Deaths involving fentanyl, fentanyl analogs, and U-47700-10 States, July–December 2016 publication-title: MMWR Morb. Mortal. Wkly. Rep. – volume: 125 start-page: 1675 year: 2017 end-page: 1681 ident: bib0145 article-title: The US opioid crisis: current federal and state legal issues publication-title: Anesth. Analg. – volume: 77 start-page: 774 year: 2016 end-page: 781 ident: bib0105 article-title: Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico publication-title: J. Stud. Alcohol Drugs – year: 2018 ident: bib0150 article-title: CBP Enforcement Statistics FY – volume: 139 start-page: 8601 year: 2017 end-page: 8611 ident: bib0015 article-title: Development of a clinically viable heroin vaccine publication-title: J. Am. Chem. Soc. – volume: 67 start-page: 349 year: 2018 end-page: 358 ident: bib0140 article-title: Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016 publication-title: MMWR Morb. Mortal. Wkly. Rep. – year: 2004 ident: bib0025 article-title: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction publication-title: Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration – volume: 66 start-page: 697 year: 2017 end-page: 704 ident: bib0070 article-title: Vital signs: changes in opioid prescribing in the United States, 2006–2015 publication-title: MMWR Morb. Mortal. Wkly. Rep. – volume: 374 start-page: 301 year: 2016 end-page: 303 ident: bib0005 article-title: Opioid prescribing for chronic pain—achieving the right balance through education publication-title: N. Engl. J. Med. – volume: 372 start-page: 241 year: 2015 end-page: 248 ident: bib0060 article-title: Supplementary Appendix: trends in opioid analgesic abuse and mortality in the United States publication-title: N. Eng. J. Med. – volume: 8 start-page: 157 year: 2007 end-page: 170 ident: bib0035 article-title: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS publication-title: Pain Med. – volume: 129 start-page: 139 year: 2014 end-page: 147 ident: bib0010 article-title: Prescription drug monitoring and dispensing of prescription opioids publication-title: Public Health Rep. – volume: 31 start-page: 112 year: 2018 end-page: 120 ident: bib0080 article-title: Current state of vaccines in psychiatry—a narrative review publication-title: Asian J. Psychiatry – volume: 15 start-page: 405 year: 2016 end-page: 424 ident: bib0090 article-title: A qualitative exploration of perceived gender differences in methamphetamine use among women who use methamphetamine on the Mexico-U.S. border publication-title: J. Ethn. Subst. Abuse – volume: 71 start-page: 821 year: 2014 end-page: 826 ident: bib0040 article-title: The changing face of heroin use in the United States: a retrospective analysis of the past 50 years publication-title: JAMA Psychiatry – volume: 372 start-page: 241 year: 2015 ident: 10.1016/j.drugalcdep.2018.08.029_bib0060 article-title: Supplementary Appendix: trends in opioid analgesic abuse and mortality in the United States publication-title: N. Eng. J. Med. doi: 10.1056/NEJMsa1406143 – volume: 30 start-page: 264 year: 2011 ident: 10.1016/j.drugalcdep.2018.08.029_bib0095 article-title: The prescription drug epidemic in the United States: a perfect storm publication-title: Drug Alcohol Rev. doi: 10.1111/j.1465-3362.2011.00291.x – volume: 66 start-page: 697 year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0070 article-title: Vital signs: changes in opioid prescribing in the United States, 2006–2015 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6626a4 – year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0120 – year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0110 – volume: 322 start-page: 164 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0115 article-title: Differential activation of dopaminergic systems in rat brain basal ganglia by morphine and methamphetamine publication-title: Neuroscience doi: 10.1016/j.neuroscience.2016.01.043 – volume: 374 start-page: 154 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0050 article-title: Relationship between nonmedical prescription-opioid use and heroin use publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1508490 – volume: 372 start-page: 241 year: 2015 ident: 10.1016/j.drugalcdep.2018.08.029_bib0055 article-title: Trends in opioid analgesic abuse and mortality in the United States publication-title: N. Engl. J. Med. doi: 10.1056/NEJMsa1406143 – volume: 34 start-page: e1 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0160 article-title: The opioid epidemic in the United States publication-title: Emerg. Med. Clin. North Am. doi: 10.1016/j.emc.2015.11.002 – volume: 374 start-page: 301 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0005 article-title: Opioid prescribing for chronic pain—achieving the right balance through education publication-title: N. Engl. J. Med. doi: 10.1056/NEJMp1512932 – year: 2004 ident: 10.1016/j.drugalcdep.2018.08.029_bib0025 article-title: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction – volume: 67 start-page: 349 year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0140 article-title: Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6712a1 – volume: 138 start-page: 112 year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0065 article-title: The opioid epidemic is an historic opportunity to improve both prevention and treatment publication-title: Brain Res. Bull. doi: 10.1016/j.brainresbull.2017.06.008 – volume: 129 start-page: 139 year: 2014 ident: 10.1016/j.drugalcdep.2018.08.029_bib0010 article-title: Prescription drug monitoring and dispensing of prescription opioids publication-title: Public Health Rep. doi: 10.1177/003335491412900207 – volume: 173 start-page: S4 year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0045 article-title: Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter? publication-title: Drug Alcohol Depend. doi: 10.1016/j.drugalcdep.2016.03.014 – volume: 31 start-page: 112 year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0080 article-title: Current state of vaccines in psychiatry—a narrative review publication-title: Asian J. Psychiatry doi: 10.1016/j.ajp.2018.02.004 – volume: 139 start-page: 8601 year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0015 article-title: Development of a clinically viable heroin vaccine publication-title: J. Am. Chem. Soc. doi: 10.1021/jacs.7b03334 – year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0085 – year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0150 – volume: 19 start-page: 5 year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0130 article-title: Vaccines to combat the opioid crisis. Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse publication-title: EMBO Rep. doi: 10.15252/embr.201745322 – volume: 66 start-page: 1197 year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0125 article-title: Deaths involving fentanyl, fentanyl analogs, and U-47700-10 States, July–December 2016 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6643e1 – year: 2009 ident: 10.1016/j.drugalcdep.2018.08.029_bib0075 – volume: 48 start-page: 1 year: 2015 ident: 10.1016/j.drugalcdep.2018.08.029_bib0100 article-title: Prescription drug abuse: from epidemiology to public policy publication-title: J. Subst. Abuse Treat. doi: 10.1016/j.jsat.2014.08.004 – volume: 125 start-page: 1675 year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0145 article-title: The US opioid crisis: current federal and state legal issues publication-title: Anesth. Analg. doi: 10.1213/ANE.0000000000002403 – volume: 15 start-page: 405 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0090 article-title: A qualitative exploration of perceived gender differences in methamphetamine use among women who use methamphetamine on the Mexico-U.S. border publication-title: J. Ethn. Subst. Abuse doi: 10.1080/15332640.2015.1070392 – year: 2018 ident: 10.1016/j.drugalcdep.2018.08.029_bib0135 – volume: 8 start-page: 157 year: 2007 ident: 10.1016/j.drugalcdep.2018.08.029_bib0035 article-title: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) publication-title: Pain Med. doi: 10.1111/j.1526-4637.2006.00259.x – year: 2017 ident: 10.1016/j.drugalcdep.2018.08.029_bib0155 – volume: 71 start-page: 821 year: 2014 ident: 10.1016/j.drugalcdep.2018.08.029_bib0040 article-title: The changing face of heroin use in the United States: a retrospective analysis of the past 50 years publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.366 – year: 2015 ident: 10.1016/j.drugalcdep.2018.08.029_bib0020 – volume: 72 start-page: 424 year: 2015 ident: 10.1016/j.drugalcdep.2018.08.029_bib0030 article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.3043 – volume: 77 start-page: 774 year: 2016 ident: 10.1016/j.drugalcdep.2018.08.029_bib0105 article-title: Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico publication-title: J. Stud. Alcohol Drugs doi: 10.15288/jsad.2016.77.774 |
SSID | ssj0000690 |
Score | 2.6490211 |
Snippet | •Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to... Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes... Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 14 |
SubjectTerms | Drug abuse Drug addiction Drug use Epidemics Help seeking behavior Medical treatment Methamphetamine Narcotics Opioids Patients Polls & surveys Polysubstance use Qualitative analysis Rural communities Rural populations Substance abuse treatment Treatment programs |
Title | Twin epidemics: The surging rise of methamphetamine use in chronic opioid users |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0376871618306872 https://dx.doi.org/10.1016/j.drugalcdep.2018.08.029 https://www.ncbi.nlm.nih.gov/pubmed/30326396 https://www.proquest.com/docview/2157473131 https://www.proquest.com/docview/2121487121 |
Volume | 193 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swELcQe-EFsY1Btw55EuIta504abw9ITTUDQ0eBoI3y5dcpUCXVGkj3vjbdxcn3SZtUiVeosTxWYl9H79LzndCHAOQH2GQJM0oE5DFgwDIDQtcErk0gjjF9g_-98tkeqO_3cV3W-Ks3wvDYZWd7vc6vdXWXcuom83RoihGP8YkGwz3iSnHdMJ6WOsJc_nHJ_WHNvbfWahzwL27aB4f45XXDenhLEfOXKnSNplnCzb_aaL-B0FbU3S-J3Y7DClP_WO-FFtYvhJDv9FW3uJ85mqUJ7JvqOqH1-Lq-rEoJfp6sNnykyT-kMum5hpFkgQdZTWTXE7a0fLiyv0k9CkbaiaqzCfQldWiqIqcW-vlvrg5_3J9Ng26YgpBpmOzCoCgWQioU1AuH2cJQ7uEBJpuKpeBNoBqFjlaGjLiMSe6AwOTNJkhOc8aTfRGbJdViYe8zRtAaRjnkaaxVQhJjMgjYqg5Qd5ATPr5s1mXaZwLXsxtH1J2b3_PvOWZt1wLMzQDodaUC59tYwMa0y-R7XeTkv6zZBI2oP28pv2L6zakHvYcYTvJX1qCUOShRSpSA_FhfZtkln_EuBKrhvuE5IVO6DgQB56T1q9LkILWxSRvn_Vo78QOX_m4m6HYXtUNvif0tIKjVjyOxIvTrxfTy1_xBxiq |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqcigXBC2PhaUYCXELu06cbNyeUEW1fR_Yit4sTzIrpZRkld2IG7-dmThZigTSSr1Eke2JHHse3yTjGSE-AJAfYZAkzSgTkMWDAMgNC1wSuTSCOMX2D_7FZTK91qc38c2WOOrPwnBYZaf7vU5vtXXXMupWc7QoitHXMckGw31iyjHdkB5-pEl8uYzBp1_qnjr2H1podMDDu3AeH-SV1w0p4ixHTl2p0jabZ4s2_2mj_odBW1t0_FQ86UCk_Ozn-UxsYbkrhv6krfyGd3NXo_wo-4aq_r4nrmY_i1KiLwibLQ8kMYhcNjUXKZIk6SirueR60o72F1fuB8FP2VAzUWU-g66sFkVV5NxaL5-L6-Mvs6Np0FVTCDIdm1UAhM1CQJ2Ccvk4SxjbJSTR1KlcBtoAqnnkaG_Iisec6Q4MTNJkjuQ9azTRC7FdViW-4nPeAErDOI80PVuFkMSI_EQMNWfIG4hJv34261KNc8WLO9vHlN3aPytveeUtF8MMzUCoNeXCp9vYgMb0W2T746SkAC3ZhA1oD9e0f7HdhtTDniNsJ_pLSxiKXLRIRWog3q-7SWj5T4wrsWp4TEhu6ISuA_HSc9L6dQlT0L6Y5PWDpvZO7ExnF-f2_OTy7I14zD0-CGcotld1g28JSq1gvxWV3yx4Gjg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twin+epidemics%3A+The+surging+rise+of+methamphetamine+use+in+chronic+opioid+users&rft.jtitle=Drug+and+alcohol+dependence&rft.au=Ellis%2C+Matthew+S.&rft.au=Kasper%2C+Zachary+A.&rft.au=Cicero%2C+Theodore+J.&rft.date=2018-12-01&rft.pub=Elsevier+B.V&rft.issn=0376-8716&rft.volume=193&rft.spage=14&rft.epage=20&rft_id=info:doi/10.1016%2Fj.drugalcdep.2018.08.029&rft.externalDocID=S0376871618306872 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0376-8716&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0376-8716&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0376-8716&client=summon |